J&J reportedly in talks to reduce offer for Elan stock

Johnson & Johnson is in talks to reduce by at least $100 million its offer to purchase an 18.4% stake in Elan, after a court ruled that part of the deal violates Elan's drug partnership with Biogen Idec, sources said. J&J and Elan declined to comment on the negotiations, which would change J&J's $1 billion cash bid but keep intact its $500 million investment in Elan's drugs.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Economics & Reimbursement Manager - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA